NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, announced today that it will participate in the Planet MicroCap Las Vegas 2026 Conference on June 17-18, 2026. President and CEO Dave Rosa is scheduled to present on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time in TRACK 6 - Raphael 3. The presentation will include commercialization updates and anticipated milestones for the company's OneRF platform, which is designed for treatment of the brain, pain, and advanced drug delivery.
In addition to the company presentation, Rosa will host one-on-one meetings with institutional investors during the conference. He also participated in a CEO interview with Planet MicroCap host Robert Kraft ahead of the event, which can be viewed here. The webcast of the presentation will be available here, and more information about the conference can be found on the conference website here.
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
This announcement matters because NeuroOne's OneRF platform represents a significant advancement in the treatment of neurological disorders, potentially offering less invasive options for patients suffering from conditions such as epilepsy, chronic pain, and other brain-related ailments. For leaders in business and technology, the company's progress signals growing opportunities in the neurotechnology sector, which is poised for expansion as minimally invasive surgical techniques gain traction. The presentation at the Planet MicroCap conference provides a platform for NeuroOne to update investors on key milestones and commercialization efforts, which could influence market perception and investment decisions in the medical technology space.
The impact of NeuroOne's technology extends beyond individual patient outcomes. By reducing the number of hospitalizations and surgical procedures, the company's solutions have the potential to lower healthcare costs systemwide. For industry observers, the development of advanced drug delivery systems and spinal cord stimulation programs indicates a broadening pipeline that could address unmet medical needs. As the company continues to innovate, its progress may shape the future of neurological care and create new opportunities for partnerships and adoption within the healthcare ecosystem.
For more information about NeuroOne and its technology, visit the company's website at nmtc1.com. The original press release is available on NewMediaWire.
